Success Metrics

Clinical Success Rate
75.0%

Based on 3 completed trials

Completion Rate
75%(3/4)
Active Trials
0(0%)
Results Posted
100%(3 trials)
Terminated
1(14%)

Phase Distribution

Ph not_applicable
1
14%
Ph phase_3
2
29%
Ph phase_4
2
29%
Ph phase_2
2
29%

Phase Distribution

0

Early Stage

2

Mid Stage

4

Late Stage

Phase Distribution7 total trials
Phase 2Efficacy & side effects
2(28.6%)
Phase 3Large-scale testing
2(28.6%)
Phase 4Post-market surveillance
2(28.6%)
N/ANon-phased studies
1(14.3%)

Highest Phase Reached

Phase 4

Trial Status & Enrollment

Completion Rate

60.0%

3 of 5 finished

Non-Completion Rate

40.0%

2 ended early

Currently Active

0

trials recruiting

Total Trials

7

all time

Status Distribution
Completed(3)
Terminated(2)
Other(2)

Detailed Status

Completed3
unknown2
Terminated1
Withdrawn1

Development Timeline

Analytics

Development Status

Total Trials
7
Active
0
Success Rate
75.0%
Most Advanced
Phase 4

Trials by Phase

Phase 22 (28.6%)
Phase 32 (28.6%)
Phase 42 (28.6%)
N/A1 (14.3%)

Trials by Status

terminated114%
withdrawn114%
completed343%
unknown229%

Recent Activity

0 active trials
Showing 5 of 7
terminatedphase_4

Scale-up of Treatment of Hepatitis C Infection Among People Who Inject Drugs

NCT02940691
completedphase_2

Short Duration Therapy of Acute Hepatitis C Genotypes 1 or 4

NCT02886624
completedphase_3

Grazoprevir (MK-5172) and Elbasvir (MK-8742) Combination in Treatment-Naïve Hepatitis C Virus Participants (MK-5172-067)

NCT02251990
unknownphase_4

Grazoprevir/Elbasvir for Treatment of Hepatitis C Virus Genotype 4 Post Kidney Transplant

NCT03359746
completedphase_2

Study to Assess Efficacy and Safety of Grazoprevir/Elbasvir Associated With Sofosbuvir and Ribavirin in HCV Genotype 1 or 4-infected Patients Who Failed Direct Acting Antivirals (DAA) Bitherapy With Sofosbuvir

NCT02647632
View all 7 trials

Clinical Trials (7)

Showing 7 of 7 trials
NCT02940691Phase 4

Scale-up of Treatment of Hepatitis C Infection Among People Who Inject Drugs

Terminated
NCT02886624Phase 2

Short Duration Therapy of Acute Hepatitis C Genotypes 1 or 4

Completed
NCT02251990Phase 3

Grazoprevir (MK-5172) and Elbasvir (MK-8742) Combination in Treatment-Naïve Hepatitis C Virus Participants (MK-5172-067)

Completed
NCT03359746Phase 4

Grazoprevir/Elbasvir for Treatment of Hepatitis C Virus Genotype 4 Post Kidney Transplant

Unknown
NCT02647632Phase 2

Study to Assess Efficacy and Safety of Grazoprevir/Elbasvir Associated With Sofosbuvir and Ribavirin in HCV Genotype 1 or 4-infected Patients Who Failed Direct Acting Antivirals (DAA) Bitherapy With Sofosbuvir

Completed
NCT03110055Not Applicable

the Effect of Grazoprevir/Elbasvir and TACE vs. TACE Alone in Prolonging Survival of Patients With Non-resectable HCV Associated HCC.

Unknown
NCT02204475Phase 3

Grazoprevir (MK-5172)/Elbasvir (MK-8742) Versus Boceprevir/Pegylated Interferon/Ribavarin for Chronic Hepatitis C Infection (MK-5172-066)

Withdrawn

All 7 trials loaded

Drug Details

Intervention Type
DRUG
Total Trials
7